股行者

Defense Threat Reduction Agency

government_agency

政府合同A · 官方确认已完成置信度 98%

披露 / 截止日期

2026-07-30

2021-03-22 至 2022-04-30

披露金额

$86.7K

以源记录当前口径为准

项目产能

—

HDTRA121P0012

证据记录

0 条价格 / 产能 / 交付信号

原始证据

点击来源可回到官方页面核验上下文和最新修订。

HDTRA121P0012 · CATALYST PHARMACEUTICALS, INC

USAspending.gov·2026-07-30·CONT_AWD_HDTRA121P0012_9700_-NONE-_-NONE-

打开官方原文

CATALYST PHARMACEUTICALS, INC received a federal award currently valued at $86,650 from Defense Threat Reduction Agency. RESEARCH AND DEVELOPMENT SERVICES FOR IND FILING OF 3,4-DIAMINOPYRIDINE PHOSPHATE.

A · 官方确认方向已确认

关系字段

产品 / 服务: RESEARCH AND DEVELOPMENT SERVICES FOR IND FILING OF 3,4-DIAMINOPYRIDINE PHOSPHATE.
项目